HRP20040910A2 - New compounds - Google Patents
New compounds Download PDFInfo
- Publication number
- HRP20040910A2 HRP20040910A2 HR20040910A HRP20040910A HRP20040910A2 HR P20040910 A2 HRP20040910 A2 HR P20040910A2 HR 20040910 A HR20040910 A HR 20040910A HR P20040910 A HRP20040910 A HR P20040910A HR P20040910 A2 HRP20040910 A2 HR P20040910A2
- Authority
- HR
- Croatia
- Prior art keywords
- group
- general formula
- compounds
- formula
- substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 89
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 41
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims abstract 4
- -1 phenylethenyl group Chemical group 0.000 claims description 50
- 229910052731 fluorine Inorganic materials 0.000 claims description 48
- 125000005843 halogen group Chemical group 0.000 claims description 30
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 125000004076 pyridyl group Chemical group 0.000 claims description 29
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 27
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 239000012453 solvate Substances 0.000 claims description 17
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 15
- 125000002252 acyl group Chemical group 0.000 claims description 15
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 14
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 14
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 14
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 14
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 14
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 125000002541 furyl group Chemical group 0.000 claims description 14
- 150000004677 hydrates Chemical class 0.000 claims description 14
- 125000002883 imidazolyl group Chemical group 0.000 claims description 14
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 14
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 14
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 14
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 14
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 14
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 14
- 125000002971 oxazolyl group Chemical group 0.000 claims description 14
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 14
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 14
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 14
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 14
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 14
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 14
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 14
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 14
- 125000000335 thiazolyl group Chemical group 0.000 claims description 14
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 13
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 12
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 8
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 8
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000011541 reaction mixture Substances 0.000 claims description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- FWNGAGUNZPZIHY-LBPRGKRZSA-N (2s)-1-[2-[[1-(6-chloropyridazin-3-yl)piperidin-4-yl]amino]acetyl]-4,4-difluoropyrrolidine-2-carbonitrile Chemical compound C1C(F)(F)C[C@@H](C#N)N1C(=O)CNC1CCN(C=2N=NC(Cl)=CC=2)CC1 FWNGAGUNZPZIHY-LBPRGKRZSA-N 0.000 claims description 2
- DOFZWSHDHHCVMM-ZDUSSCGKSA-N (2s)-4,4-difluoro-1-[2-[(1-pyrazin-2-ylpiperidin-4-yl)amino]acetyl]pyrrolidine-2-carbonitrile Chemical group C1C(F)(F)C[C@@H](C#N)N1C(=O)CNC1CCN(C=2N=CC=NC=2)CC1 DOFZWSHDHHCVMM-ZDUSSCGKSA-N 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000004306 triazinyl group Chemical group 0.000 claims description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 7
- PVRDHPNNGYYTPN-AWEZNQCLSA-N 6-[4-[[2-[(2s)-2-cyano-4,4-difluoropyrrolidin-1-yl]-2-oxoethyl]amino]piperidin-1-yl]pyridazine-3-carbonitrile Chemical compound C1C(F)(F)C[C@@H](C#N)N1C(=O)CNC1CCN(C=2N=NC(=CC=2)C#N)CC1 PVRDHPNNGYYTPN-AWEZNQCLSA-N 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 40
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 239000011737 fluorine Substances 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical group [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 7
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 125000001544 thienyl group Chemical group 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 4
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- PBXJEAYKZGZMIE-YFKPBYRVSA-N (2s)-1-(2-chloroacetyl)-4,4-difluoropyrrolidine-2-carbonitrile Chemical compound FC1(F)C[C@@H](C#N)N(C(=O)CCl)C1 PBXJEAYKZGZMIE-YFKPBYRVSA-N 0.000 description 3
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 3
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000011533 pre-incubation Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- HCJRVTIJLZPAPW-GXKRWWSZSA-N (2s)-4,4-difluoro-1-[2-[(1-pyrazin-2-ylpiperidin-4-yl)amino]acetyl]pyrrolidine-2-carbonitrile;dihydrochloride Chemical compound Cl.Cl.C1C(F)(F)C[C@@H](C#N)N1C(=O)CNC1CCN(C=2N=CC=NC=2)CC1 HCJRVTIJLZPAPW-GXKRWWSZSA-N 0.000 description 2
- DMQSZIMWOFNPNR-WDSKDSINSA-N (2s,4s)-1-(2-chloroacetyl)-4-fluoropyrrolidine-2-carbonitrile Chemical compound F[C@H]1C[C@@H](C#N)N(C(=O)CCl)C1 DMQSZIMWOFNPNR-WDSKDSINSA-N 0.000 description 2
- VVZYUTHLZPRBJG-WHFBIAKZSA-N (2s,4s)-1-(2-chloroacetyl)-4-fluoropyrrolidine-2-carboxamide Chemical compound NC(=O)[C@@H]1C[C@H](F)CN1C(=O)CCl VVZYUTHLZPRBJG-WHFBIAKZSA-N 0.000 description 2
- YKIUKRCSLWXOOK-UHFFFAOYSA-N 1-pyrazin-2-ylpiperidin-4-amine Chemical compound C1CC(N)CCN1C1=CN=CC=N1 YKIUKRCSLWXOOK-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- GELVZYOEQVJIRR-UHFFFAOYSA-N 2-chloropyrazine Chemical compound ClC1=CN=CC=N1 GELVZYOEQVJIRR-UHFFFAOYSA-N 0.000 description 2
- VSCBATMPTLKTOV-UHFFFAOYSA-N 2-tert-butylimino-n,n-diethyl-1,3-dimethyl-1,3,2$l^{5}-diazaphosphinan-2-amine Chemical compound CCN(CC)P1(=NC(C)(C)C)N(C)CCCN1C VSCBATMPTLKTOV-UHFFFAOYSA-N 0.000 description 2
- DKOWCDDMXRSLQZ-CKUXDGONSA-N 6-[4-[[2-[(2s)-2-cyano-4,4-difluoropyrrolidin-1-yl]-2-oxoethyl]amino]piperidin-1-yl]pyridine-3-carbonitrile;dihydrochloride Chemical compound Cl.Cl.C1C(F)(F)C[C@@H](C#N)N1C(=O)CNC1CCN(C=2N=CC(=CC=2)C#N)CC1 DKOWCDDMXRSLQZ-CKUXDGONSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 2
- CSTBBLHIGMTEAZ-UHFFFAOYSA-N chloroform;ethyl acetate;hexane Chemical compound ClC(Cl)Cl.CCCCCC.CCOC(C)=O CSTBBLHIGMTEAZ-UHFFFAOYSA-N 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- WXMKQWCHJVTGSJ-UHFFFAOYSA-N n-(1-pyrazin-2-ylpiperidin-4-yl)acetamide Chemical compound C1CC(NC(=O)C)CCN1C1=CN=CC=N1 WXMKQWCHJVTGSJ-UHFFFAOYSA-N 0.000 description 2
- YLWUSMHZABTZGP-UHFFFAOYSA-N n-piperidin-4-ylacetamide Chemical compound CC(=O)NC1CCNCC1 YLWUSMHZABTZGP-UHFFFAOYSA-N 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- FBQFSNRSVLFGLE-LURJTMIESA-N tert-butyl (2s)-2-carbamoyl-4,4-difluoropyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(F)(F)C[C@H]1C(N)=O FBQFSNRSVLFGLE-LURJTMIESA-N 0.000 description 2
- SQGNCVVKJIZGLC-BQBZGAKWSA-N tert-butyl (2s,4s)-2-carbamoyl-4-fluoropyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@@H](F)C[C@H]1C(N)=O SQGNCVVKJIZGLC-BQBZGAKWSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- YHJOBAWVEDSCGF-BYPYZUCNSA-N (2s)-1-(2-chloroacetyl)-4,4-difluoropyrrolidine-2-carboxamide Chemical compound NC(=O)[C@@H]1CC(F)(F)CN1C(=O)CCl YHJOBAWVEDSCGF-BYPYZUCNSA-N 0.000 description 1
- KZMRGTASBWZPFC-BYPYZUCNSA-N (2s)-1-fluoropyrrolidine-2-carboxylic acid Chemical class OC(=O)[C@@H]1CCCN1F KZMRGTASBWZPFC-BYPYZUCNSA-N 0.000 description 1
- QTLNACQQSGNJIG-JTQLQIEISA-N (2s)-1-tert-butyl-2-carbamoyl-4,4-difluoropyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)N1CC(F)(F)C[C@]1(C(N)=O)C(O)=O QTLNACQQSGNJIG-JTQLQIEISA-N 0.000 description 1
- RRQDQYAEZGKHOB-DFWYDOINSA-N (2s)-4,4-difluoropyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.NC(=O)[C@@H]1CC(F)(F)CN1 RRQDQYAEZGKHOB-DFWYDOINSA-N 0.000 description 1
- YIEACUBSPQGCLW-MMALYQPHSA-N (2s,4s)-4-fluoropyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.NC(=O)[C@@H]1C[C@H](F)CN1 YIEACUBSPQGCLW-MMALYQPHSA-N 0.000 description 1
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical group [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 1
- YCWRPKBYQZOLCD-UHFFFAOYSA-N 1-(2-chloroacetyl)pyrrolidine-2-carbonitrile Chemical compound ClCC(=O)N1CCCC1C#N YCWRPKBYQZOLCD-UHFFFAOYSA-N 0.000 description 1
- OTWVFHZMWFGHSJ-UHFFFAOYSA-N 1-fluoropyrrolidine Chemical group FN1CCCC1 OTWVFHZMWFGHSJ-UHFFFAOYSA-N 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- YCJMDLIMUBMVRG-UHFFFAOYSA-N 6-(4-aminopiperidin-1-yl)pyridine-3-carbonitrile Chemical compound C1CC(N)CCN1C1=CC=C(C#N)C=N1 YCJMDLIMUBMVRG-UHFFFAOYSA-N 0.000 description 1
- OALNRYDCNPHFLM-HNNXBMFYSA-N 6-[4-[[2-[(2s)-2-cyano-4,4-difluoropyrrolidin-1-yl]-2-oxoethyl]amino]piperidin-1-yl]pyridine-3-carbonitrile Chemical compound C1C(F)(F)C[C@@H](C#N)N1C(=O)CNC1CCN(C=2N=CC(=CC=2)C#N)CC1 OALNRYDCNPHFLM-HNNXBMFYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- GJYVZUKSNFSLCL-UHFFFAOYSA-N dichloromethanol Chemical compound OC(Cl)Cl GJYVZUKSNFSLCL-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000000231 kidney cortex Anatomy 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- RQFUXZHSNWVTSP-UHFFFAOYSA-N n-[1-(5-cyanopyridin-2-yl)piperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)CCN1C1=CC=C(C#N)C=N1 RQFUXZHSNWVTSP-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- WUOQXNWMYLFAHT-QMMMGPOBSA-N tert-butyl n-[(3s)-piperidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CCCNC1 WUOQXNWMYLFAHT-QMMMGPOBSA-N 0.000 description 1
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
Abstract
Prezentirani izum se odnosi na nove, važne inhibitore DPP-IV enzima opće formule (I),koji sadržavaju atome fluora.
Description
Prezentirani izum se odnosi na nove spojeve opće formule (I) koji imaju inhibitorno djelovanje na enzim dipeptidil-peptidaza-IV, kao i na njegove soli, solvate i izomere, na terapijsku aplikaciju spojeva opće formule (I), na farmaceutske sastave koji sadržavaju spojeve opće formule (I), na proces njihove proizvodnje i na nove intermedijere opće formule (II), (III), (V), (VII), VIII) i (IX).
Enzim dipeptil-peptidaza-IV (DPP-IV), koji je identičan s površinskim glikoproteinom limfocita CD26, polipeptidom molarne mase od 110 k Daltona, je formiran u tkivima i organima sisavaca. Taj enzim može se naći, kod ostalih, u jetri, u Langerhans-ovim kanalima, u korteksu bubrega, u plućima, i u određenim tkivima prostate i tankog crijeva. Signifikantno DPP-IV djelovanje može se uočiti nadalje u tjelesnim tekućinama (na primjer u plazmi, serumu i urinu).
DPP-IV je serin proteaza tip enzima, koji ima jedinstvenu specifičnost za cijepanje dipeptida od N-terminalnog peptida kada je primarno predzadnja amino kiselina prolin, alanin ili hidroksi prolin.
DPP-IV enzim je odgovoran za dekompoziciju glukagonu sličnih peptida, peptid-1 (GLP-1 i peptid-2 (GLP-2) u organizmu. Enzim GLP-1 snažno stimulira produkciju inzulina pankreasa, tako da ima direktni, povoljan učinak na homeostazu glukoze, zbog toga DPP-IV inhibitori su pogodni za tretiranje i prevenciju diabetesa melitusa neovisnog o inzulinu (NIDDM) i druge bolesti koje su povezane s aktivitetom enzima DPP-IV uključujući ali ne ograničavajući na dijabetes, pretilost, hiperlipidemiju, dermatološka oštećenja ili oštećenja mukozne membrane, psorijazu, poremećaje crijeva, konstipaciju, autoimune poremećaje kao što su encefalomijelitis, dopunjene posredovane poremećaje kao što su glomerulonefritis, lipodistrofiju, i oštećenja tkiva, psihosomatske, depresivne i neuropsihijatrijske bolesti kao što su tjeskoba, depresija, besanica, šizofrenija, epilepsija, spazmi i kronična bol, HIV infekcije, alergije, upale, artritisi, odbacivanje transplantata, visoki tlak, kongestivno zatajenje srca, tumori, i abortusi uzrokovani stresom.
Naš cilj je bio proizvesti nove, učinkovite, stabilne i sigurne DPP-IV inhibitore.
Našli smo da spojevi opće formule (I) gdje R1 stoji za: - dušik koji sadržava aromatski dio koji se sastoji od jednog ili dva aromatska prstena , preferirano piridil, piridazinil, piridinil, pirazinil, imidazolil, pirazolil, tiazolil, izotiazolil, oksazolil, izoksazolil, oksadiazolil, kvinolinil, izokvinolinil, cinolinil, ftalazinil, kvinazolinil, kvinoksa-linil, benzamidazolil, indazolil, benzotiazolil, benziso-tiazolil, benzoksazolil, benzisoksazolil, tetrazolil ili triazinil prsteni; koji su, po izboru mono-ili disubstituirani neovisno jedan od drugoga s jednom ili dvije od slijedećih skupina: C1-4alkil skupinom, C1-4 alkoksi skupinom, atomom halogena, trihalogenmetil skupinom, metiltio skupinom, nitro skupinom, cijano skupinom, amino skupinom ili fenil skupinom; ili
- tienil ili furil ili benzil skupinom; ili
- p-toluensulfonil skupinom; ili
- acil skupinom formule R1a-CO, gdje R1a znači C1-4 alkil skupina, fenil skupina;
fenil, piridil ili feniletenil skupina substituirana s jednom ili više C1-4 alkil- i/ili C1-4 alkoksi- ili nitro skupina ili atomom halogena; feniletil skupina, ili feniletil skupina substituirana s alkilen-dioksi skupinom; piperidin-1-il, 4-metil-piperazin-1-il, ili pirolidin-1-ili skupinom;
B stoji za skupinu u skladu s formulom (1) ili (2) ili (3) ili (4) ili (5) ili (6) ili (7);
R2 stoji za atom vodika ili atom fluora;
R3 stoji za atom fluora-
pored toga soli, izomeri i solvati tih spojeva imaju značajnu prednost s obzirom na njihov aktivitet, trajanje djelovanja, stabilnost i toksičnost u komparaciji s stanjem u struci. U skladu s prihvatljivom terminologijom, konfiguracija atoma ugljika na poziciji 2 fluorpirolidin skupine je povoljno S, s obzirom na to da atom ugljika na poziciji 4 je S ili R.
Jedno ostvarenje prezentiranog izuma uključuje spojeve opće formule (I)-gdje R1 znači dušik-koji sadržava aromatski dio koji se sastoji od jednog ili dva aromatska prstena, preferirano piridil, piridazinil, pirimidinil, pirazinil, imidazolil, pirazolil, tiazolil, izotiazolil, oksazolil, izoksazolil, oksadiazolil, kvinolinil, izokvinolinil, cinolinil, ftalazinil, kvinazolinil, kvinoksalinil, benzimidazolil, indazolil, benzotiazolil, benzisotiazolil, benzoksazolil ili benzisoksazolil prsten; koji je, u navedenom slučaju, nezavisno jedan od drugog mono- ili disubstituiran s jednom ili dvije sljedeće skupine: C1-4 alkil skupinom, C1-4 alkoksi skupinom, atomom halogena, trihalogenmonometil skupinom, metiltio skupinom, nitro skupinom, cijano skupinom; ili
- tienil ili furil skupinom; ili
- p-toluensulfonil skupinom; ili
- acil skupinom formule R1a-CO, gdje R1a znači C1-4 alkil skupina; fenil skupina; fenil, piridil ili feniletil skupina substituirana s jednom ili više alkil- i/ili alkoksi- ili nitro skupina ili atomom halogena; feniletil skupina, ili
feniletil skupina substituirana s alkilen-dioksi skupinom; piperidin-1-il, 4-metilpiperazin-1-il, pirolidin-1-il skupinom;
B stoji za
- skupinu formule (1) ili (2) ili (3) ili (4) ili (5) ili (6) ili (7);
R2 stoji za atom vodika ili atom fluora;
R3 stoji za atom fluora-
i soli, izomere, njihove solvate tautomera i hidrate.
Drugo ostvarenje prezentiranog izuma uključuje spojeve opće formule (I)- gdje R1 znači dušik-koji sadržava aromatski dio koji se sastoji od jednog ili dva aromatska prstena, preferirano piridil, piridazinil, pirimidinil, pirazinil, imidazolil, pirazolil, tiazolil, izotiazolil, oksazolil, izoksazolil, oksadiazolil, kvinolinil, izokvinolinil, cinolinil, ftalazinil, kvinazolinil, kvinoksalinil, benzimidazolil, indazolil, benzotiazolil, benzisotiazolil, benzoksazolil ili benzisoksazolil prsten; koji je u navedenom slučaju, nezavisan jedan od drugog mono- ili disubstituiran s jednom ili dvije sljedeće skupine: C1-4 alkil skupinom, C1-4 alkoksi skupinom, atomom halogena, trihalogenmonometil skupinom, metiltio skupinom, nitro skupinom, cijano skupinom; ili
tienil ili furil skupinom; ili
p-toluensulfonil skupinom; ili
acil skupinom formule R1a-CO, gdje R1a znači C1-4 alkil skupina; fenil skupina; fenil, piridil ili feniletil skupina substituirana s jednom ili više alkil- i/ili alkoksi- ili nitro skupina ili atomom halogena; feniletenil skupina, ili feniletil skupina substituirana s alkilen-dioksi skupinom; piperidin-1-il, 4-metil-piperazin-1-il, pirolidin-1-il skupinom;
B stoj i za
- skupinu formule (1);
R2 stoji za atom vodika ili atom fluora;
R3 stoji za atom fluora-
i soli, izomere, njihove tautomere solvata i hidrata.
Drugo ostvarenje prezentiranog izuma uključuje spojeve opće formule (I)- gdje R1 znači dušik-koji sadržava aromatski dio koji se sastoji od jednog ili dva aromatska prstena, preferirano piridil, piridazinil, pirimidinil, pirazinil, imidazolil, pirazolil, tiazolil, izotiazolil, oksazolil, izoksazolil, oksadiazolil, kvinolinil, izokvinolinil, cinolinil, ftalazinil, kvinazolinil, kvinoksalinil, benzimidazolil, indazolil, benzotiazolil, benzisotiazolil, benzoksazolil ili benzisoksazolil prsten; koji je u navedenom slučaju, neovisno jedan od drugog mono- ili disubstituiran s jednom ili dvije sljedeće skupine: C1-4 alkil skupinom, C1-4 alkoksi skupinom, atomom halogena, trihalogenmonometil skupinom, metiltio skupinom, nitro skupinom, cijano skupinom;
ili
tienil ili furil skupinom; ili
p-toluensulfonil skupinom; ili
acil skupinom formule R1a-CO, gdje R1a znači C1-4 alkil skupina; fenil skupina; fenil, piridil ili feniletil skupina substituirana s jednom ili više alkil- i/ili alkoksi- ili nitro skupina ili atomom halogena; feniletenil skupina, ili feniletil skupina substituirana s alkilen-dioksi skupinom; piperidin-1-il, 4-metil-piperazin-1-il, pirolidin-1-il skupinom;
B stoji za
- skupinu formule (2);
R2 stoji za atom vodika ili atom fluora;
R3 stoji za atom fluora-
i soli, izomere, njihove tautomere solvata i hidrata.
Drugo ostvarenje prezentiranog izuma uključuje spojeve opće formule (I)- gdje R1 znači dušik-koji sadržava aromatski dio koji se sastoji od jednog ili dva aromatska prstena, preferirano piridil, piridazinil, pirimidinil, pirazinil, imidazolil, pirazolil, tiazolil, izotiazolil, oksazolil, izoksazolil, oksadiazolil, kvinolinil, izokvinolinil, cinolinil, ftalazinil, kvinazolinil, kvinoksalinil, benzimidazolil, indazolil, benzotiazolil, benzisotiazolil, benzoksazolil ili benzisoksazolil prsten; koji je u navedenom slučaju, nezavisan jedan od drugog mono- ili disubstituiran s jednom ili dvije sljedeće skupine: C1-4 alkil skupinom, C1-4 alkoksi skupinom, atomom halogena, trihalogenmonometil skupinom, metiltio skupinom, nitro skupinom, cijano skupinom;
ili
tienil ili furil skupinom; ili
p-toluensulfonil skupinom; ili
acil skupinom formule R1a-CO, gdje R1a znači C1-4 alkil skupina; fenil skupina; fenil, piridil ili feniletil skupina substituirana s jednom ili više alkil- i/ili alkoksi- ili nitro skupina ili atomom halogena; feniletenil skupina, ili feniletil skupina substituirana s alkilen-dioksi skupinom; piperidin-1-il, 4-metil-piperazin-1-il, pirolidin-1-il skupinom;
B stoj i za
- skupinu formule (3);
R2 stoji za atom vodika ili atom fluora;
R3 stoji za atom fluora-
i soli, izomere, njihove tautomere solvata i hidrata.
Drugo ostvarenje prezentiranog izuma uključuje spojeve opće formule (I)- gdje R1 znači dušik-koji sadržava aromatski dio koji se satoji od jednog ili dva aromatska prstena, preferirano piridil, piridazinil, pirimidinil, pirazinil, imidazolil, pirazolil, tiazolil, izotiazolil, oksazolil, izoksazolil, oksadiazolil, kvinolinil, izokvinolinil, cinolinil, ftalazinil, kvinazolinil, kvinoksalinil, benzimidazolil, indazolil, benzotiazolil, benzisotiazolil, benzoksazolil ili benzisoksazolil prsten; koji je u navedenom slučaju, neovisno jedan od drugog mono- ili disubstituiran s jednom ili dvije sljedećih skupina: C1-4 alkil skupinom, C1-4 alkoksi skupinom, atomom halogena, trihalogenmonometil skupinom, metiltio skupinom, nitro skupinom, cijano skupinom;
ili
tienil ili furil skupinom; ili
p-toluensulfonil skupinom; ili
acil skupinom formule R1a-CO, gdje R1a znači C1-4 alkil skupina; fenil skupina; fenil, piridil ili feniletil skupina substituirana s jednom ili više alkil- i/ili alkoksi- ili nitro skupina ili atomom halogena; feniletenil skupina, ili feniletil skupina substituirana s alkilen-dioksi skupinom; piperidin-1-il, 4-metil-piperazin-1-il, pirolidin-1-il skupinom;
B stoj i za
- skupinu formule (4) ili (5);
R2 stoji za atom vodika ili atom fluora;
R3 stoji za atom fluora-
i soli, izomere, njihove tautomere solvata i hidrata.
Drugo ostvarenje prezentiranog izuma uključuje spojeve opće formule (I)- gdje R1 znači dušik-koji sadržava aromatski dio koji se sastoji od jednog ili dva aromatska prstena, preferirano piridil, piridazinil, pirimidinil, pirazinil, imidazolil, pirazolil, tiazolil, izotiazolil, oksazolil, izoksazolil, oksadiazolil, kvinolinil, izokvinolinil, cinolinil, ftalazinil, kvinazolinil, kvinoksalinil, benzimidazolil, indazolil, benzotiazolil, benzisotiazolil, benzoksazolil ili benzisoksazolil prsten; koji je u navedenom slučaju, neovisno jedan od drugog mono- ili disubstituiran s jednom ili dvije sljedeće skupine: C1-4 alkil skupinom, C1-4 alkoksi skupinom, atomom halogena, trihalogenmonometil skupinom, metiltio skupinom, nitro skupinom, cijano skupinom;
ili
tienil ili furil skupinom; ili
p-toluensulfonil skupinom; ili
acil skupinom formule R1a-CO, gdje R1a znači C1-4 alkil skupina; fenil skupina; fenil, piridil ili feniletil skupina substituirana s jednom ili više alkil- i/ili alkoksi- ili nitro skupina ili atomom halogena; feniletenil skupina, ili feniletil skupina substituirana s alkilen-dioksi skupinom; piperidin-1-il, 4-metil-piperazin-1-il, pirolidin-1-il skupinom;
B stoj i za
- skupinu formule (6) ili (7) ;
R2 stoji za atom vodika ili atom fluora;
R3 stoji za atom fluora-
i soli, izomere, njihove tautomere solvata i hidrata.
Preferirani spoj opće formule (1) je onaj gdje R1, B ili R2 su one skupine koje su pobrojane u Tablicama 1 do 3 uključujući svaku kombinaciju, na primjer (2S)-4,4-difluor-1-(2-{[8-(2-pirimidinil)-8-azabiciklo[3.2.1]okt-3-il]exo-amino}acetil)-2-pirolidin karbonitril; (2S,4S)-4-fluor-1-(2-{[8-(2-pirazinil)-8-azabiciklo-[3.2.1]-okt-3-il]exo-amino}acetil-2-pirolidinkarbo nitril; (2S)-4,4-difluor-1-(2-{[1-(2-pirazinil)piperidin-4-il]amino}acetil)-2-pirolidin karbonitril; (2S)-4,4-difluor-1-(2-{[1-(5-cianopiridin-2-il)piperidin-4-il]amino}acetil)-2-pirolidine karbonitril; (2S)-4,4-difluor-1-(2-{[1-(6-klorpiridazin-3-il)piperidin-4-il]amino}acetil)-2-pirolidine karbonitrile; (2S)-4,4-difluor-1-(2-{[1(6-cijanopiridazin-3-il)piperidin-4-il]amino}acetil-2-pirolidin karbonitril;
Pojam „dušik-koji sadržava aromatski dio koji se sastoji od jednog ili dva aromatska prstena" uključuje sve takve sustave prstena poznate prije od datuma prezentacije naše patentne aplikacije.
Pojam „atom halogena" znači atom fluora, klora, broma ili joda. „C1-4 alkil skupina,, i «C1-4 alkoksi skupina» znači ravni ili razgranati lanac alifatske ugljikovodične skupine koja sadržava 1-4 atoma dušika.
Spojevi opće formule (I) u skladu s našim izumom mogu se pripraviti alkilacijom primarnih amina opće formule (II) gdje značenje R1 i B je isto kao što je dato gore - s kloracetil izvedenog od opće formule (III) - gdje značenje R2 i R3 je kao što je dato gore, ako se zahtjeva, transformacije nastalih spojeva u jednu od njezinih soli ili solvata (Shema 1).
U slučaju alkilacije kloracetila izvedenog od opće formule (III) koji je primijenjen u suvišku, a nastali klorovodik je vezan s različitim kiselim sredstvima za vezanje, preferirano s bazom, kao što je na primjer trietilamin, kalijev karbonat, 1,8-diazabiciklo [5.4.0]undec-7-ene (DBU) ili 2-terc-butilimino-2-dietilamino-1,3-dimetil-perhidro-1,3,2-diazafosforin-vezan na smolu (PBEMP)-, koja je poznata kao super baza. Reakcija se preferirano izvodi na temperaturi između 25 i 70°C.
Primarni amini opće formule (II) su pripravljeni u dva koraka sinteze (sheme 2). U prvom koraku polaznog cikličnog sekundarnog amina opće formule (IV)- gdje značenje Y je atom vodika, acetil, ili tert-butoksikarbonil skupina- koje su arilirane, preferirano s aril halogenidima opće formule (X), gdje značenje R1 je isto kao što je navedno gore a X stoji za otom halogena. Ovisno o značenju R1 reakcija arilacije može se izvesti u polarnom, protičkom ili aprotičkom otapalu, između 25 i 150°C, preferirano u alkoholima (etanol, n-butanol, n-pentanol), ili bez otapala u mikrovalnoj pećnici, upotrebom veziva, naprimjer u suvišku amina, ili DBU.
Za polazni materijal slobodnih amina ili zaštićeno sekundarne amine opće formule (IV) iz literature je poznato- da se koriste, tako 4-acetaminopiperidin (B= formula (1), Y= COCH3) (US-3225037);
4-tert-butoksikarbonilaminopiperidin (B= formula (1), Y=COOC(CH3)3) ((J.Med.Chem, 1999, 42, 2706) ; 3- (S) –tert-butoksikarbonilaminopiperidin (B= formula (2)) i 3-(S)-tert-butokaikarbonilaminopirolidin (B= formula(3)) (Synth.Comm. 1998, 28, 3919) u zadnja dva slučaja Y= COOC(CH3)3; tert-butil 8-azabiciklo[3.2.1]okt-3-il-ekso-karbamat (B=formula (4)), tert-butil 8-azabiciklo[3.2.1]-okt-3-il-endo-karbamat (B= formula (5)) (J.Med.Chem 1991, 34, 656), tert-butil-9-azabiciklo[3.3.1]-non-3-il-ekso-karbamat (B=formula (6)) i tert-butil-9-asabiciklo-[3.3.1]-non-3-il-endo-karbamat (B= formula (7)), (J.Med.Chem 1993, 36, 3720)) (Y=COOC (CH3) 3).
U drugom koraku protektivna skupina Y je odstranjena iz ariliranog amina opće formule (V)- gdje značenje R1 i B su isti kao što je definirano gore- s kiselom hidrolizom. Reakcija se izvodi u vodenoj klorovodičnoj kiselini ili u etanolnoj otopini vodikovog klorida na temperaturi između 25 i 78°C da se dobiju alifatski ili ciklični primarni amini opće formule (II)- gdje značenje R1 i B su isti kao što je gore definirano. Ako R1 stoji za acil skupinu formule R1a-CO, spojevi opće formule (IV)- gdje je značenje Y tert-butoksikarbonil skupina su reagirali s kiselinom porijeklom od opće formule R1a-COZ-gdje značenje Z je ostatna skupina, preferirano atom klora-korisno na temperaturi oko 0°C, upotrebom anorganske i organske baze, preferirano trietiamin kao kiselo sredstvo vezanja. Od spojeva opće formule (V) protektivna skupina Y je rascijepljena u kiselim uvjetima, preferirano upotrebom trifluoroctene kiseline u otopini diklormetana, na 0-30°C, da se dobiju amini opće formule (II), gdje je značenje R1 je skupina formule R1a-CO.
1-(2-kloracetil)-2-pirolidinkarbonitrili opće formule (III)-gdje značenje R2 i R3 su isti kao što je gore definirano- su pripremljeni u četiri koraka sinteze (Shema 3).
Polazni spojevi su fluorprolin derivati, preferirano L-fluorprolin derivati- gdje značenje R2 i R3 su isti kao što je definirano gore- s dušikom zaštićenim s tert-butoksikarbonil skupinom. Ti spojevi mogu se pripremiti metodama opisanim u literaturi (Tetrahedron Lett. 1998, 39, 1169). U prvom koraku miješani anhidrid je pripremljen s pivaloil kloridom ili esterom kloroformne kiseline, potom karbamoil derivati opće formule (VIII)- gdje značenje R2 i R3 je isto kao što je gore definirano- su formirani.
Reakcija se preferirano izvodi u halogeniranom otapalu (CHCl3, CH2Cl2), na 0-25°C.
U drugom koraku tert-butoksikarbonil skupini je rascijepljen u otopini etanol hidrogen klorida. Hidroliza se izvodi na 0-25°C i hidrokloridi karboksamida opće formule (VIII)- gdje je značenje R2 i R3 je isto kao što je definirano gore- su dobiveni.
Fluoropirolidinkarboksamidi opće formule (VIII) tako dobiveni su u trećem koraku acilirani s kloracetil kloridom, preferirano na 0°C, u halogeniranom otapalu (CHCl3, CH2Cl2). Tako su formirani kloracetilkarbamoil derivati opće formule (IX)- gdje značenje R2 i R3 je isto kao što je definirano gore.
U četvrtom koraku kloracetilkarbamoil derivati opće formule (IX) su dehidrirani da se dobiju kloracetilcijano derivati opće formule (III)- gdje značenje R2 i R3 je isto kao što je definirano gore. Dehidracija se preferirano izvodi s fosfornim oksikloridom u dihidrometanu na točki vrenja reakcijske smjese.
[image]
[image]
Biološka ispitivanja
Inhibitorno djelovanje spojeva opće formule (I) na DPP-IV enzima je određeno slijedećom metodom:
Uvjeti primjenje analize:
DPP-IV, izvor: otopljeni sirovi ekstrakt od CaCo/Tc-7 stanica, Sadržaj: 0.8-1 μg/analiza
Substrat: H-Gly-Pro-AMC (Bachetn)
Reakcija: 1 sat predinkubacije uzorka na 37°C
vrijeme reakcije 3 0 minuta na 37°C
Otopina za prekidanje reakcije: pufer 1M Na-acetat (pH=4.2)
Reakcijska smjesa: 10 μl otopine enzima
10 μl test spoja ili pufera za anlizu
55 μl pufera za analizu
25 μl substrata
300 μl otopine za prekidanje reakcije
Mjerenje: spektrofotometrijsko određivanje s Tecan plate čitačem (Ex: 360 nm Em: 465 nm)
Reakcija DPP-IV enzima i H-Gly-Pro-AMC substrata se izvodi oslobađanjem AMC (7-amino-4-metilkumarina) na 37°C u 100 mM tris-HCl, pH=7.5 (pufer za analizu): Standardna krivulja AMC je linearna sve do 31.25 μM koncentracije, zato se koristi jedinica za relativnu fluorescenciju (RFU) formirane AMC. Određuje se upotrebom ekstinkcije od 360 nm i filtera emisije od 465 (30 μs vrijeme integracije, Gain 25, Br. Bljesaka 50) s Tečan Spectrofluor Plus čitačem ploča. Pod tim uvjetima reakcija enzima je linearna kroz najmanje 30 min, a ovisnost enzima je linearna sve do 25 μg proteina (sve do 700 RFU). Upotrebom 1-0.8 μg ekstrakta proteina Km za H-gly-pro-AMC je 50 μM. Koncentracija substrata viša od 500 μM uzrokuje problemom fluorescentne detekcije (unutarnji efekt filtera) se može riješiti dilucijom uzorka.
Analiza je namijenjena za što je moguće učinkovitiju detekciju aktivnosti inhibitora što je moguće učinkovitije, upotrebom 60 min vremena predinkubacije na 37°C. Analiza se izvodi dodavanjem 0.8-1 μg ekstrakta proteina u 10 μl otopine enzima (upotrebom pufera za analizu: 100 mM tris-HCl, pH=7.5) u bunariće koji sadržavaju test spojeve u 10 μl volumenu i 55 μl pufera za analizu (65 μl pufera za analizu u slučaju kontrole). Nakon razdoblja predinkubacije, reakcija počinje dodavanjem 25 μl lmM otopine substrata H-gly-pro-AMC (250 μM finalne koncentracije) . Finalni test volumen je 100 μl a test otopina sadržava 1% DMSO koji potječe od otopine test spoja. Vrijeme reakcije je 30 min na 37°C, a reakcija se prekida dodavanjem 300 μl pufera Na-acetata, pH=4.2. Fluorescencija (RFU) formiranog AMC je određena upotrebom 360 nm ekscitacije i 465 emisije filtra u Tečan spectrofluor Plus plate čitaču (30 μs vrijeme integracije, Gain 25 br. Bljeskova 50). Postotak inhibicije se izračuna upotrebom RFU kontrole u RFU slijepe probe.
IC50 vrijednosti karakteristične za inhibicijski učinak enzima spojeva opće formule (I) u skladu s izumom su manje od 100 nM.
Spojevi opće formule (I) i njezini solvati soli i izomeri mogu se formulirati za oralno ili parenteralno primjenjive farmaceutske sastave metodama poznatim od prije, njihovim miješanjem s jednim ili više prihvatljivih farmaceutskih ekscipijensa i mogu se aplicirati kao jedinstveni oblik doziranja.
Primjereni jedinstveni oblik doziranja obuhvaća oralne oblike, kao što su tablete, čvrste ili mekane želatinozne kapsule, prašci, granule i oralne otopine ili suspenzije, sublingvalne, bukalne, intratrahealne, intraokularne, intranazalne oblike, za inhalaciju, topičke, transdermalne, sub-kutane, intramuskularne ili intra-venozne oblike, rektalne oblike i implatanate. Za topičku aplikaciju, spojevi izuma mogu se koristiti kao kreme, gelovi, masti ili losioni.
Kao primjer, jedinstveni oblik doziranja za spoj u skladu s izumom, u obliku tableta, može sadržavati sljedeće sastojke:
Spoj opće formule (I) 50.0 mg
Manitol 223.75 mg
Natrij kroskarameloza 6.0 mg
Kukuruzni škrob 15.0 mg
Hidroksipropil metilceluloza 2.25 mg
Magnezij stearat 3.0 mg
Dnevna doza spojeva opće formule (I) može ovisiti o brojnim faktorima, tako o prirodi i ozbiljnosti bolesti pacijenta, načinu aplikacije i o samom spoju.
Daljnje pojedinosti izuma su pokazane putem primjera dolje, bez ograničavanja zahtjeva na primjere.
Slika 1 pokazuje spojeve opće formule (I),
Slika 2 pokazuje spojeve opće formule (II),
Slika 3 pokazuje spojeve opće formule (III),
Slika 4 pokazuje spojeve opće formule (IV),
Slika 5 pokazuje spojeve opće formule (V),
Slika 6 pokazuje spojeve opće formule (VI),
Slika 7 pokazuje spojeve opće formule (VII),
Slika 8 pokazuje spojeve opće formule (VIII),
Slika 9 pokazuje spojeve opće formule (IX),
Slika 10 pokazuje spojeve opće formule (X),
Slika 11 pokazuje formulu (1),
Slika 12 pokazuje formulu (2),
Slika 13 pokazuje formulu (3),
Slika 14 pokazuje formulu (4),
Slika 15 pokazuje formulu (5),
Slika 16 pokazuje formulu (6),
Slika 17 pokazuje formulu (7) .
Primjeri
Primjer 1
(2S)-4,4-difluor-1-(2-{[8-(2-pirimidinil)-8-azabiciklo[3.2.1]okt-3-il] exo-amino}acetil] -2-pirolidin karbonitril
Značenje R1 je 2-pirimidinil skupina, B označava skupinu formule (4), R2 i R3 znače atom fluora u općoj formuli (I).
a.) tert-butil 8-(2-pirimidinil)-8-azabiciklo[3.2.1]okt-3-il-exo-karbamat s općom formulom (V) - gdje R1 j e 2-pirimidinil, Y je COOC(CH3)3, B je skupina(4)
14. 7 g tert-butil 8-azabiciklo[3.2.1]okt-3-il-exo-karbamat (65 mmol) (J.Med. Chem. 1991, 34, 656) i 8.93 g 2-klorpirimidin (78 mmol) i 12.7 ml 1,8-diazabiciklo[5.4.0]undec-7-ene (DBU) (85 mmol) se rastopi u 230 ml 1-pentanola i zagrije pod refluksom kros 4 sata. Otapalo se evaporira a ostatak se rastopi u 250 ml kloroforma i ispere s 2x300 ml vode, osuši iznad Na2SO4, i purificira kolonskom kromatografijom upotrebom n-heksan-etil acetat-kloroform (1:1:1) kao eluentom da bi se dobili bijeli kristali koj e se usitni s n-heksanom.
Prinos: 13.25 g (67%). T.t. : 113-115°C. 1H-NMR (400 MHz, CDCl3) : δ 1.34(s, 9H), 1.49 (t, 2H), 1.66-1.97(m, 6H), 3.89(br, 1H), 4.61(d, 2H), 6.60(t+br, 1+1H), 8.34(d, 2H).
b.) 8- (2-pirimidinil) -8-azabiciklo [3.2.1] okt -3 - il-exo-amin s općom formulom (II) -gdje R1 i B su navedeni u koraku la.)
13 g tert-butil 8- (2-pirimidinil)-8-azabiciklo[3.2.1]okt-3-il-exo-karbamata (43 mmol) se rastopi u smjesi od 120 ml trifluoroctene kiseline i 120 ml diklormetana. Otopina se miješa kroz 30 min i evaporira. Ostatak se rastopi u 50 ml dikiormetana i evaporira. Taj postupak se ponovi tri puta a posljednja organska otopina se ekstrahira s 100 ml zasićene vodene otopine natrij karbonata. Slojevi se odvoje a vodena faza se ispere s 4x50 ml diklormetana. Spojeni organski slojevi se osuše iznad Na2SO4 i evaporiraju što rezultira bijelim praškom koji se samelje s n-heksanom. Prinos: 6.7 g (77%). T.t.: 56-59°C. 1H-NMR (400 MHz, DMS0-d6): δ 1.29(t, 2H), 1.64-1.98(m, 6H), 3.19(m, 1H), 4.58(dd, 2H), 6.57(t, 1H), 8.33(d, 2H).
c.) tert-butil (2S) -2-(aminokarbonil)-4,4-difluor-1-pirolidin karboksilat opće formule (VII) gdje R2 i R3 opće formule (VII) gdje R2 i R3 znače atom fluora.
5.7 g (22.7 mmol) tert-butil (2S)-2-(aminokarbonil)-4,4-difluor-2-pirolidinkarboksilne kiseline (Tetraheron Lett. 1998, 39, 1169) se rastopi u 57 ml diklormetana i u tu otopinu se doda 3.8 ml (27.2 mmol) trietilamina. U nastalu smjesu ukapa se, na -15°C 3 ml (25 mmol) pivaloil klorida i smjesa se miješa na toj temperaturi 1 sat, potom se doda kap po kap 7 ml 25 % vodene otopine amonijaka i smjesa se miješa kroz 1 sat. Reakcijska smjesa se ispere s vodom, 1N otopinom NaOH, osuši iznad natrij sulfata i evaporira. Nakon dodavanja dietil etera 3.94 g (69 %) gore navedeni produkt kristalizira.
T.t.: 136-138 °C. 1H-NMR (400 MHz, CDCl3): δ 1.48(s,9H), 2.3-2.9 (m, 3-CH2), 3.69 (br, neznatno) + 3.86 (m, znatno) (5-CH2), 4.53 (br,2-CH), 6.0 (br, znatno) + 6.81 (br ,neznatno) (NH2).
d.) (2S)-4,4-difluor-2-pirolidinkarboksamid hidroklorid opće formule (VIII) gdje R2 i R3 znače atom fluora 3.93 g (15.7 mmol) tert-butil (2S)-2-(aminokarbonil)-4,4-difluor-1-pirolidinkarboksilata se rastopi u 75 ml 25 % etanolne otopine hidrogen klorida i miješa se na sobnoj temperaturi kroz 4 sata. U nastalu suspenziju doda se 150 ml dietil etera, nastali bijeli kristalni materijal se odfiltrira. Dobije se 2.55 g (87 %) gore navedenog produkta.
T.t.: 232-233°C. 1H-NMR (400 MHz, DMSO-d6): δ 2.43-2.51(m,neznatno) i 2.81-3.05 (m, znatno) (3-CH2), 3.71 (t,2H,5-CH2), 4.46 (t,1H,2-CH), 7.81 (s, 1H,)+8.12 (s, 1H) (NH2), 10.12 (br,2H,NH2+).
e.) (2S)-1-(2-kloracetil)-4,4-difluor-2-pirolidin-karboksamid opće formule (IX) gdje R2 i R3 znače atom fluora
2.54 g (13.6 mmol) (2S)-4,4-difluor-2-pirolidinkaboksamid hidroklorida se suspendira u 25 ml diklormetana i u tu suspenziju se doda 4.1 ml (29.3 mmol) trietilamina. U nastalu smjesu doda se kap po kap, ispod -10°C 1.2 ml (15 mmol) kloracetil klorida u 20 ml diklormetana. Nakon 1 sat miješanja suspenzija se prelije u 450 ml etil acetata, precipitirani trietilamin hidroklorid se odfiltrira, filtrat se evaporira i purificra kromatografijom upotrebom eluenta kloroform-metanol 4:1. Dobije se 3.0 g (97%) gore navedenog produkta u obliku bezbojnog ulja.
1H-NMR (400 MHz, DMSO-dG) : δ 2. 34 -2. 52 (m, 1H) + 2. 66-2. 83 (m, 1H) {3-CH2), 4,07-4.2 9 (m,2H, 5 -CH2), 4.40(qv, 2H, CH2Cl), 4.71(m, 1H, 2-CH), 7.17(br, 1H)+7.42(d, 1H) (NH2).
f.) (2S) -1- (2-kloracetil)-4,4-difluor-2-pirolidinkarbonitril opće formule (III) gdje R3 i R3 znače atom fluora
10.4 g (46 mraol) (2S)1-1(2-kloracetil)-4,4-difluor-2-pirolidin karboksamid ae rastopi u 23 0 ml diklormetanola i u to se doda 13 ml (140 mmol) fosfornog oksiklorida. Smjesa se zagrije kroz 24 sata (ako je preostali polazni materijal potom doveden do refluksa dalje). Tijekom refluksa otopina postane svijetlo žuta a ljepljivi kruti materijal precipitira. Otopina se prelije u drugu posudu i u to se doda 50 g kalij karbonata. Nakon miješanja jedan sat kruta sol se odfiltrira a otopina se evaporira. Dobiveno svij etlo šuto ulj e se razvij e s n-heksanom. Dobiveni žuti kristali sg sakupe i doda se 7 0 ml dietil-etera. Tako se onečišćenja rastope i dobije se kruti produkt kao čisti bijeli kristali. Prinos: 6.0 g (56 %). T.t.: 86-87 C
1H-NMR (4 00 MHz, CDCl3) : δ 2.76-2.98(m, 2H, 3-CH2), 3.92-4.2 6(m, 2H,5-CH2), 4.46(qv, 2H, CH2Cl), 5.11(m, 1H, 2-CH).
g.) (2S)-4,4-difluor-l-(2-{[8-(2-pirimidinil)-8-azabiciklo [3.2.1]okt-3-il]exo-amino}acetil) -2 -pirolidinkarbonitril
6.13 g 8- (2-pirimidinil) -8-azabiciklo [3.2.1] okt-3 -il-exo-amina (30 mmol) i 5.74 g (2S) -1-(2-kloracetil)-4,4-difluor-2-pirolidinkarbo-nitrila (27,5 mmol) i 12.5 ml trietilamina (90 mmol) se rastopi u 250 ml suhog acetonitrila i miješa na 70°C kroz 3 sata i potom na sobnoj temperaturi preko noći. Potom se smjesa evaporira da se dobije smeđkasto gusto ulje koje se purificira kolonskom kromatografijom upotrebom kloroform-metanola (6:1) kao eluenta što rezultira s čvrstim produktom koji se kristalizira iz abs. etanola. Prinos: 5.7 g (77%=. T.t.: 162-163 °C.
1H-NMR (400 MHz, DMSO-d6) : δ 1. 32 (td, 2H), 1. 6-2. 0 (m, 7H), 2.6-2.9(m, 2H), 2.85(tt, 1H), 3.0-3.5(m, 2H), 3.97(ddd, 1H), 4.13(ddd, 1H), 4.61(m, 2H), 5.05 (d.d., 1H), 6.60(t, 1H), 8.35(m, 2H).
Primjer 2
(2S,4S)-4-fluor-1-(2-{[8-(2-pirazinil)-8-azabiciklo[3.2.1]-okt-3-il]exo-amino}acetil]-2-pirolidin karbonitril
dihidroklorid
U općoj formuli (I) značenje R1 je 2-pirazinil skupina, B označava skupinu formule (4), R2 znači atom vodika a R3 znači atom fluora.
a.) tert-butil 8-(2-pirazinil)-8-azabiciklo[3.2.1]okt-3-il-exo-karbamat s općom formulom (V) - gdje R1 je 2-pirazinil, Y je COOC(CH3)3, B je skupina (4)
0.54 ml klorpirazina (6 mmol) i 1.13 g tert-butil 8-benzil-8-azabiciklo[3.2.1]okt-3-il-exo-karbamata (6 mmol) 0.97 ml 1.8-diazabiciklo[5.4.0]undec-7-ene (DBU)(6.5 mmol) se rastopi u 40 ml 1-pentanola i zagrije do refluksa kroz 50 sati. Otapalo se evaporira a ostatak se rastopi u 50 ml kloroforma i ispere s 4x3 0 ml vode, osuši iznad Na2SO4, i purificira kolonskom kromatografijom upotrebom n-heksan-etil acetat-kloroform (1:1:1) kao eluenta ds bi se dobili bijeli kristali koj i se usitne s n-heksanom.
Prinos: 0.55 g (36%). T.t.: 122-123°C. 1H-NMR (400 MHz, DMSO-d6) : δ 1.34 (s, 9H), 1.44-1.66(m, 2H), 1. 67-1. 99 (m, 6H), 3.88(m, 1H), 4.65(bs, 2H), 6.59(d, 1H), 7.77(d, 1H), 8.07(d.d., 1H), 8.17(d, 1H).
b) 8-(2-pirazinil)-8-azabiciklo[3.2.1]okt-3-il-exo-amin s općom formulom (II) -gdje R1 i B su navedeni u koraku 2a.)
3.85 g tert-butil 8-(2-pirimidinil)-8-azabiciklo[3.2.1]okt-3-il-exo-karbamata (1.26 mmol) se rastopi u 20 ml 12% etanolne klorovodične kiseline i otopi na se miješa kroz 7 sati. Doda se 20 ml vode u nastalu suspenziju a pH se podesi na 11 s vodenim kalijevim hidroksidom. Slojevi se odvoje, organski faze se osuše, evaporira i purificira kolonskom kromatografijom upotrebom etilacetat-metanol-25% vodena otopina NH3 (17:3:1) kao eluent da se dobije svijetlo bijelo ulje. Prinos: 167 mg (65%). 1H-NMR (4 00 MHz, DMS0-d6): δ 1.29(t, 2H), 1.62-1.83 (m, 4H), 1.84-2.00(m, 2H), 3.12(sp, 1H), 4.57(dd, 2H), 7.74(d, 1H), 8.05(dd, 1H), 8.15(d, 1H).
c.) tert-butil (2S,4S)-2-(aminokarbonil)-4-fluor-1-pirolidin karboksilat opće formule (VII) gdje R2 znači atom vodika a R3 znači atom fluora.
1.63 g (7 mmol) (2S,4S)-1-(tertbutokaikarbonil)-4-fluor-2-pirolidinkarboksilne kiseline (Tetraheron Lett. 1998, 39, 1169) se rastopi u 25 ml diklormetana i u to se doda 1.2 ml (8.4 mmol) trietilamina. U nastalu smjesu ukapa se, na -15°C 0.86 ml (7 mmol) pivaloil klorida i smjesa se miješa 1 sat, reakcijska smjesa se ispere s vodom, 1N otopinom NaOH i ponovo s vodom, osuši iznad natrij sulfata i evaporira. 0.88 g (54 %) navedenog produkta se kristalizira iz dietil etera. Točka tališta 173-175°C. 1H-NMR (400 MHz, DMSO-d6): δ 1.38 (s,9H), 2.07-2.25 (m, 2H, 3-CH2), 3.49-3.67 (m,2H,5-CH2), 4.13(d,1H,2-CH), 5.07 i 5.35(br,1H,4-H), 6.91 + 7.17 (br,2H,NH2).
d.) (2S,4S)-4-fluor-2-pirolidinkarboksamid hidroklorid
U općoj formuli (VIII) R2 znači atom vodika a R3 znači atom fluora
4 g (17.2 mmol) tert-butil (2S,4S)-2-(aminokarbonil)-4-fluor-1-pirolidinkarboksilata se rastopi u 75 ml 2 5 % etanolne otopine hidrogen klorida i miješa se na sobnoj temperaturi kroz 4 sata. Dobivena bijela kristalna substancija se odfiltrira, ispere s eterom i osuši. Dobije se 2.56 g (88 %) navedenog produkta.
T.t. : 250-251°C .
1H-NMR (400 MHz, DMSO-d6): δ 2.31(t,1H, 2 .49-2 . 65 (m, 1H), 3.46(m,1H), 4.30(d.d.,1H), 5.37(d,1H), 7.71(s,1H) i 8. 09 (s,1H) (NH2), 9.7 (br,2H,NH2+).
e.) (2S,4S)-1-(2-kloracetil)-4-fluor-2-pirolidinkarboksamid U općoj formuli (IX) R2 znači atom vodika a R3 znači atom fluora
2.54 g (15 mmol) (2S,4S)-4-fluor-2-pirolidinkaboksamid hidroklorida se suspendira u 60 ml diklormetana i u tu suspenziju se doda 4.6 ml (33 mmol) trietilamina. U dobivenu smjesu, 1.27 ml(16 mmol) kloracetil klorid rastopi se u 15 ml diklormetana i doda se kap po kap na ispod -10°C. Nakon 1 sat miješanja suspenzija se prelije u 500 ml etilacetata, precipitirani trietilamin hidroklorid se odfiltrira, filtrat se koncentrira i purificira kromatografijom upotrebom smjese kloroform-metanol 4:1.
Tako dobivenih 3.0 g (97%) gore navedenog produkta u obliku bezbojnog ulja koje kristalizira tijekom stajanja. Njegova točka tališta je 95-96 °C.
1H-NMR (400 MHz, DMSO-d6): δ 2.22-2.50 (m, 2H, 3-CH2), 3.57-4.04 (m,2H,5-CH2), 4.36 (qv,2H,CH2Cl), 5.22 (d,0.5H) i 5.39 (d,0.5H)(4-CH), 7.03 (s,0.74H) i 7.22 (s,1H) i 7.56 (s,0. 26H) (NH2).
f.) (2S,4S)-1-(2-kloracetil)-4-fluor-2-pirolidinkarbonitril
U općoj formuli (III) R2 znači atom vodika a R3 znači atom fluora
1.73 g (46 mmol) (2S,4S)-1-(2-kloracetil)-4-fluor-2-pirolidin karboksamida se rastopi u smjesi od 2 0 ml suhog acetonitrila i 30 ml diklormetana i u to se doda 32 ml (25 mmol) fosfornog oksiklorida. Smjesa se dovede do refluksa kroz 24 sata. Otopina se prelije u drugu bocu i u to se doda 50 g kalij karbonata i smjesa se miješa jedan sat. Kruta sol se odfiltrira a nakon evaporacije filtrata dobije se svijetlo žuto ulje koje se purificira kromatografski upotrebom 9:1 smjese kloroform i metanol. Čisti gore navedeni produkt je 0.6 g(43%) bijele kristalne krutine. T.t.: 134-136 C
1H-NMR (400 MHz, CDCl3): δ 2.23-2.62 (m, 2H, 3-CH2), 3.59-4.06 (m,2H,5-CH2), 4.46 (qv,2H,CH2Cl), 4.99 (m,1H,2-CH), 5.36 (m,0.5H) i 5.64 (m,0.5)(4-H).
g.) (25,45)-4-fluor-1-(2-{[8-(2-pirazinil)-8-azabiciklo[3.2.1]oktan-3-il]exoamino}acetil)-2-pirolidinkarbonitril dihidroklorid opće formule (I) gdje R1 znači 2-pirazinil skupine, B znači skupinu formule (4), R2 stoji za atom vodika a R3 stoji za atom fluora.
243 mg (1.2 mmol) 8-(2-pirazinil)-8-azabiciklo[3.2.1]okt-3-il-exo-amina reagira s 191 mg (1 mmol) (2S, 4S)-1-(2-kloracetil)-4-fluor-2-pirolidinkarbonitrila kao što je opisano u Primjeru 1/g). Produkt se purificira kromatografijom upotrebom 4:1 smjese kloroforma i metanola i onda se pripremi njegov dihidroklorid. Tako se dobije 125 mg (29%) spoja u obliku bijelih kristala. T.t.: 201-202°C.
1H-NMR (400 MHz, DMSO-d6): δ 1. 76-1. 80 (m, 4H), 1.94-2.01 (m, 4H), 2.47-2.51 (m,2H), 3.64-3.80 (m,1H), 3.79-4.03 (m,2H), 4.15 (m,1H), 4.67 (m,2H), 5.03 (m,1H), 5.52 (d,1H), 7.86 (s,1H), 8.15 (dd,1H), 8.28 (d,2H), 8.90 i 9.00 (s,2H).
Primjer 3
(2S)-4,4-difluor-1-(2-{[1-(2-pirazinil)piperidin-4-il]amino}acetil)-2-pirolidin karbonitril dihidroklorid
Značenje R1 je 2-pirazinil skupina, B označava skupinu formule (1), R2 i R3 znače atom fluora u općoj formuli (I) .
a.) 1-(2-pirazinil)-4-acetamino-piperidin opće formule (V) gdje R1 je 2-pirazinil, Y je COOC(CH3)3, B je skupina (1) 0.45 ml klorpirazina (5 mmol) i 1.6 g 4-acetaminopiperidina (10 mmol) se rastopi u 15 ml 1-pentanola i zagrije do refluksa kroz 14 sati. Otapalo se evaporira a ostatak se purificira kolonskom kromatografijom upotrebom etil acetat -metanol- 25% vodena otopina NH3 (17:3:1) kao eluenta da se dobije 0.81 g (76%) gore navedenog kristalnog produkta. T.t.: 158-160°C. 1H-NMR (200 MHz, DMSO-d6): δ 1. 34 (dq, 2H), 1. 78 (m, 5H), 3.03(dt,2H), 3. 74-3. 89 (m, 1H), 4.21(td,2H), 7.77 (d, 1H, 3'-H), 7.80 (s,1H,NH), 8.05 (dd, 1H, 5'-H), 8.31(d,1H, 6'-H).
b.) 1-(2-pirazinil)-4-amino-piperidin opće formule (II)-gdje R1 i B su navedeni u koraku 3a.)
697 mg 1-(2-pirazinil)-4-acetamino-piperidina (3.2 mmol) se rastopi u 15 ml 2 N klorovodične kiseline i otopina se zagrije sve do refluksa kroz 8 sati. Nakon hlađenja smjesa se tretira s 2 0% natrij kloridom i vodena otopina se ispere s 4 x 20 ml diklormetana. Spojeni organski slojevi se osuše iznad Na2SO4 i evaporiraju da bi se dobilo 2 92 mg (52%) gore navedenog produkta u obliku žutih kristala.
T.t.: 113-115°C.
1H-NMR (200 MHz, DMSO-d6-CDCl6): δ 1. 09-1. 36 (m, 2H), 1.78(d,2H), 2.78-3.31(m,4H), 3.54 (m, 1H), 7.76 (d, 1H, 3'-H), 8.03 (dd, 1H, 5'-H) 8.29(d,1H, 6'-H).
c.) (2S)-4,4-difluor-1-(2-{[1-(2-pirazinil)piperidin-4-il]amino}acetil)-2-pirolidin karbonitril dihidroklorid opće formule (I) gdje je R1 2-pirazinil skupina, B znači skupinu formule (1), R2 i R3 znače atom fluora.
63 mg 1-(2-pirazinil)-4-amino-piperidina (0.32 mmol) i 62 mg (2S)-1-(2-kloracetil)-4,4-difluor-2-pirolidin karbonitrila (0.32 mmol) i 285 mg polimera vezanog na 2-tert-butilimino-2-dietilamino-1,3-dimetil-perhidro-1,3,2-diazafosforina (PMEMP)(0.73 mmol)se rastopi u 20 ml suhog acetonitrila i miješa se na 55°C kroz 8 sat. Smola se odstrani filtracijom, filtrat se koncentrira vakumom a ostatak se purificira kolonskom kromatografijom korištenjem kloroform-metanol (9:1) kao eluenta da se dobije ulje, koje se tretira s klorovodičnom kiselinom u dietileteru i dobije se 83 mg (60 %) imenovanog spoja kao bijeli kristali.
T.t.: 158-160 °C. 1H-NMR (400 MHz, DMSO-d6): δ 1.54 (m, 2H), 2.15 (m,2H), 2.80-295 (m,4H), 4.20-4.25 (m,4H), 4.55 (d,2H), 5.20 (t,1H), 7.00 (d,1H), 7.87 (dd,1H), 8.50 (d,1H), 9.38 (br,2H).
Primjer 4
(2S)-4,4-difluor-1-(2-{[1-(5-cijanopiridin-2-il)piperidin-4-il]amino}acetil)-2-pirolidin karbonitril dihidroklorid Značenje R1 je 5-cijano-piridin-2-il skupina, B znači skupinu formule (1), R2 i R3 znači atom fluora u općoj formuli (I).
a.) 1-(5-cijanopiridin-2-il)-4-acetamino-piperidin opće formule (V)- gdje je R1 5-cijanopiridin-2-il, Y je COCH3, B je skupina (1)
Slijedeći proceduru navedenu za primjer 3a), izoliran je gore navedeni kristalni produkt. Točka tališta je 246-251°C. 1H-NMR(200 MHz, DMSO-d6): δ 1.19-1.39 (m, 2H), 1.82 (m, 5H), 3.04-3.18(m,2H), 3.85(m,1H), 4.29(dd,2H), 6.94(d,1H), 7.82(dd, 1H), 8.46(d,1H).
b.) 1-(5-cijanopiridin-2-il)-4-amino-piperidin opće formule (II)- gdje R1 i B su dati u koraku 4a.).
Slijedeći proceduru navedenu za primjer 3a), izoliran je gore navedeni kristalni produkt. T.t.: je 65-68°C. 1H-NMR(200 MHz, CDCl3-DMSO-d6): δ 1.16-1.38 (m,2H), 1.83-1.92 (m, 2H), 2.89-3.06 (m,2H), 4.26 (dd,2H), 6.54 (d,1H), 7.50 (dd,1H), 8.29 (d, 1H).
c.) (2S)-4,4-difluor-1-(2-{[1-(5-cijanopiridin-2-il)piperidin-4-il]amino}acetil)-2-pirolidinkarbonitril dihidroklorid
Slijedeći proceduru navedenu za primjer 3c), izoliran je gore navedeni kristalni produkt, Točka tališta je 146-147°C. 1H-NMR(DMSO-d6): δ 1.5 6(m,2H), 2.15 (d,2H), 2.92 (m,4H), 4.20 (m,4H), 4.55 (d,2H), 5.20 (t,2H), 7.01 (d,1H), 7.88 (d,1H), 8.49 (dd,1H), 9.38 (d,2H).
Slijedeći proceduru navedenu za Primjere 1-2, spojevi pobrojani u Tablici 1 su proizvedeni kao slobodne baze ili kao soli.
Tablica 1.
[image]
[image]
[image]
[image]
[image]
Slijedeći proceduru navedenu za Primjere 3-4, spojevi pobrojane u Tablici 2 su proizvedeni kao slobodne baze ili kao soli.
Tablica 2.
[image]
[image]
[image]
[image]
Slijedeći proceduru navedenu za Primjere 1-4, spojevi opće formule (I) pobrojani u Tablici 3 su proizvedeni kao slobodne baze ili kao soli.
Tablica 3.
[image]
[image]
[image]
Slijedeći proceduru navedenu za Primjere la) i 2a) proizvedeni su intermedijerni spojevi opće formule (V) pobrojani u Tablici 4.
Tablica 4.
[image]
[image]
[image]
[image]
Slijedeći proceduru navedenu za Primjere 1a) i 2a) proizvedeni su intermedijerni spojevi opće formule (V) pobrojani u Tablici 5.
Tablica 5.
[image]
[image]
[image]
Slijedeći proceduru navedenu za Primjere 3a) i 4a) proizvedeni su intermedijerni spojevi opće formule (V) pobrojani u Tablici 6. (Y=Ac(acetil) ili Boc=tert butiloksi-karbonil).
[image]
[image]
[image]
[image]
[image]
Slijedeći proceduru navedenu za Primjere lb) i 2b) proizvedeni su intermedijerni spojevi opće formule (II) pobrojani u Tablici 7.
Tablica 7.
[image]
[image]
[image]
[image]
Slijedeći proceduru navedenu za Primjere lb) i 2b) proizvedeni su intermedijerni spojevi opće formule (II) pobrojani u Tablici 8.
Tablica 8.
[image]
[image]
[image]
Slijedeći proceduru navedenu za Primjere 3b) i 4b) proizvedeni su intermedijerni spojevi opće formule (II) pobrojani u Tablici 9.
Tablica 9.
[image]
[image]
[image]
[image]
[image]
Claims (29)
1. Spojevi opće formule (I) naznačeni time, da
R1 znači dušik -kojeg sadržava aromatski dio koji se sastoji od jednog ili dva aromatska prstena, preferira se piridil, piridazinil, pirazinil, imidazolil, pirazolil, tiazolil, izotiazolil, oksazolil, izooksazolil, oksadiazolil, qvino-linil, izokvinolinil, cinnolinil, ftalazinil, kvinazolinil, kvinoksalinil, benzimidazolil, indazolil, benzotiazolil, benzisotiazolil, benzoksazolil ili benzisoksazolil, tetrazolil, triazinil prsten; koji je u navedenom slučaju, nezovisno jedan o drugom mono- ili disubstituiran s jednom ili dvije od slijedećih skupina: C1-4 alkil skupinama, C1-4 alkoksi skupinama, atomom halogena, trihalogenmetil skupinom, metiltio skupinom, nitro skupinom, cijano skupinom, amino skupinom ili fenil skupinom; ili
- tienil, furil ili benzil skupinom; ili
- p-toluensulfonil skupinom; ili
- acil skupinom formule Ria-CO, gdje Ria znači C1-4 alkil skupina, fenil skupina; fenil, piridil ili feniletenil skupina supstituirana s jednom ili više alkil- i/ili alkoksi- ili nitro-skupina ili atomom halogena; feniletenil ili feniletil skupinu substituiranu s alkilen-dioksi skupinom; piperidin-1-il, 4-metilpiperazin-1-il, pirolidin-1-il skupinu, B stoj i za
- skupinu formule (1) ili (2) ili (3) ili (4) ili (5) ili (6) ili (7) ;
R2 stoji za atom vodika ili atom fluora;
R3 stoji za atom fluora -
i njihove soli, izomere, tautomere, solvate i hidrate.
2. Spojevi iz zahtjeva 1 opće formule (I)- naznačeni time, da
R1 znači dušik -kojeg sadržava aromatski dio koji se sastoji od jednog ili dva aromatska prstena, preferira se piridil, piridazinil, pirimidinil, pirazinil, imidazolil, pirazolil, tiazolil, izotiazolil, oksazolil, izoksazolil, oksadiazolil, qvinolinil, izokvinolinil, cinnolinil, ftalazinil, kvinazo-linil, kvinoksalinil, benzimidazolil, indazolil, benzotiazo-lil, benzisotiazolil, benzoksazolil ili benzisoksazolil prsten; koji je u navedenom slučaju, neovisno jedan o drugom mono- ili disubstituiran s jednom ili dvije od slijedećih skupina: C1-4 alkil skupinama, C1-4 alkoksi skupinama, atomom halogena, trihalogenmetil skupinom, metiltio skupinom, nitro skupinom, cijano skupinom; ili
- tienil ili furil skupinom; ili
- p-toluensulfonil skupinom; ili
- acil skupinom formule R1a-CO, gdje R1a znači C1-4 alkil skupina, piridil ili feniletenil skupina supstituirana s jednom ili više alkil- i/ili alkoksi- ili nitro-skupina ili atom halogena; feniletenil ili feniletil skupinu substituiranu s alkilen-dioksi skupinom; piperidin-1-il, 4-metilpiperazin-1-il, pirolidin-1-il skupinu,
B stoj i za
- skupinu formule (1) ili (2) ili (3) ili (4) ili (5) ili (6) ili (7);
R2 stoji za atom vodika ili atom fluora;
R3 stoji za atom fluora -
i njihove soli, izomere, tautomere, solvate i hidrate.
3. Spojevi iz zahtjeva 2 opće formule (I)- naznačeni time, da R1 znači dušik -kojeg sadržava aromatski dio koji se sastoji od jednog ili dva aromatska prstena, preferira se piridil, piridazinil, pirimidinil, pirazinil, imidazolil, pirazolil, tiazolil, izotiazolil, oksazolil, izoksazolil, oksadiazolil, qvinolinil, izokvinolinil, cinnolinil, ftalazinil, kvinazolinil, kvinoksalinil, benzimidazolil, indazolil, benzotiazolil, benzisotiazolil, benzoksazolil ili benzisoksazolil prsten; koji je u navedenom slučaju, neovisno jedan o drugom mono- ili disubstituiran s jednom ili dvije od slijedećih skupina: C1-4 alkil skupinama, C1-4 alkoksi skupinama, atomom halogena, trihalogenmetil skupinom, metiltio skupinom, nitro skupinom, cijano skupinom; ili
- tienil ili furil skupinom; ili
- p-toluensulfonil skupinom; ili
- acil skupinom formule R1a-CO, gdje R1a znači C1-4 alkil skupinu, fenil skupinu; fenil, piridil ili feniletenil skupina supstituirana s jednom ili više alkil- i/ili alkoksi- ili nitro-skupina ili atom halogena; feniletenil ili feniletil skupina substituirana s alkilen-dioksi skupinom; piperidin-1-il, 4-metilpiperazin-1-il, pirolidin-1-il skupinu,
B stoji za
- skupinu formule (1)
R2 stoji za atom vodika ili atom fluora;
R3 stoji za atom fluora -
i njihove soli, izomere, tautomere, solvate i hidrate.
4. Spojevi iz zahtjeva 2 opće formule (I)- naznačeni time, da
R1 znači dušik -kojeg sadržava aromatski dio koji se sastoji od jednog ili dva aromatska prstena, preferira se piridil, piridazinil, pirimidinil, pirazinil, imidazolil, pirazolil, tiazolil, izotiazolil, oksazolil, izoksazolil, oksadiazolil, qvinolinil, izokvinolinil, cinnolinil, ftalazinil, kvinazolinil, kvinoksalinil, benzimidazolil, indazolil, benzotiazolil, benzisotiazolil, benzoksazolil ili benzisoksazolil prsten; koji je u navedenom slučaju, neovisno jedan o drugom mono- ili disubstituiran s jednom ili dvije od slijedećih skupina: C1-4 alkil skupinama, C1-4 alkoksi skupinama, atomom halogena, trihalogenmetil skupinom, metiltio skupinom, nitro skupinom, cijano skupinom; ili
- tienil ili furil skupinom; ili
- p-toluensulfonil skupinom; ili
- acil skupinom formule R1a-CO, gdje R1a znači C1-4 alkil skupinu, fenil skupinu; fenil, piridil ili feniletenil skupina supstituirana s jednom ili više alkil- i/ili alkoksi- ili nitro-skupina ili atom halogena; feniletenil ili feniletil skupina substituirana s alkilen-dioksi skupinom; piperidin-1-il, 4-metilpiperazin-1-il, pirolidin-1-il skupinu,
B stoji za
- skupinu formule (2)
R2 stoji za atom vodika ili atom fluora;
R3 stoji za atom fluora -
i njihove soli, izomere, tautomere, solvate i hidrate.
5. Spojevi iz zahtjeva 2 opće formule (I)- naznačeni time, da
R1 znači dušik -kojeg sadržava aromatski dio sastavljen od jednog ili dva aromatska prstena, preferira se piridil, piridazinil, pirimidinil, pirazinil, imidazolil, pirazolil, tiazolil, izotiazolil, oksazolil, izoksazolil, oksadiazolil, qvinolinil, izokvinolinil, cinnolinil, ftalazinil, kvinazolinil, kvinoksalinil, benzimidazolil, indazolil, benzotiazolil, benzisotiazolil, benzoksazolil ili benzisoksazolil prsten; koji je u navedenom slučaju, neovisno jedan o drugom mono- ili disubstituiran s jednom ili dvije od slijedećih skupina: C1-4 alkil skupinama, C1-4 alkoksi skupinama, atomom halogena, trihalogenmetil skupinom, metiltio skupinom, nitro skupinom, cijano skupinom,; ili
- tienil ili furil skupinom; ili
- p-toluensulfonil skupinom; ili
- acil skupinom formule R1a-CO, gdje R1a znači C1-4 alkil skupinu, fenil skupinu; fenil, piridil ili feniletenil skupina supstituirana s jednom ili više alkil- i/ili alkoksi- ili nitro-skupina ili atom halogena; feniletenil ili feniletil
skupina substituirana s alkilen-dioksi skupinom; piperidin-1-il, 4-metilpiperazin-1-il, pirolidin-1-il skupinu,
B stoj i za
- skupinu formule (3)
R2 stoji za atom vodika ili atom fluora;
R3 stoji za atom fluora -
i njihove soli, izomere, tautomere, solvate i hidrate.
6. Spojevi iz zahtjeva 2 opće formule (I)- naznačeni time, da
R1 znači dušik -kojeg sadržava aromatski dio sastavljen od jednog ili dva aromatska prstena, preferira se piridil, piridazinil, pirimidinil, pirazinil, imidazolil, pirazolil, tiazolil, izotiazolil, oksazolil, izoksazolil, oksadiazolil, qvinolinil, izokvinolinil, cinnolinil, ftalazinil, kvinazolinil, kvinoksalinil, benzimidazolil, indazolil, benzotiazolil, benzisotiazolil, benzoksazolil ili benzisoksazolil prsten; koji je u navedenom slučaju, neovisno jedan o drugom mono- ili disubstituiran s jednom ili dvije od slijedećih skupina: C1-4 alkil skupinama, C1-4 alkoksi skupinama, atomom halogena, trihalogenmetil skupinom, metiltio skupinom, nitro skupinom, cijano skupinom,; ili
- tienil ili furil skupinom; ili
- p-toluensulfonil skupinom; ili
acil skupinom formule R1a-CO, gdje R1a znači C1-4 alkil skupinom, fenil skupinom; fenil, piridil ili feniletenil skupina supstituirana s jednom ili više alkil- i/ili alkoksi-ili nitro-skupina ili atom halogena; feniletenil ili feniletil skupina substituirana s alkilen-dioksi skupinom; piperidin-1-il, 4-metilpiperazin-1-il, pirolidin-1-il skupinu,
B stoji za
- skupinu formule (4) ili (5)
R2 stoji za atom vodika ili atom fluora;
R3 stoji za atom fluora -
i njihove soli, izomere, tautomere, solvate i hidrate.
7. Spojevi iz zahtjeva 2 opće formule (I)- naznačeni time, da
R1 znači dušik -kojeg sadržava aromatski dio sastavljen od jednog ili dva aromatska prstena, preferira se piridil, piridazinil, pirimidinil, pirazinil, imidazolil, pirazolil, tiazolil, izotiazolil, oksazolil, izoksazolil, oksadiazolil, qvinolinil, izokvinolinil, cinnolinil, ftalazinil, kvinazolinil, kvinoksalinil, benzimidazolil, indazolil, benzotiazolil, benzisotiazolil, benzoksazolil ili benzisoksazolil prsten; koji je u navedenom slučaju, neovisno jedan o drugom mono- ili disubstituiran s jednom ili dvije od slijedećih skupina: C1-4 alkil skupinama, C1-4 alkoksi skupinama, atomom halogena, trihalogenmetil skupinom, metiltio skupinom, nitro skupinom, cijano skupinom,; ili
- tienil ili furil skupinom; ili
- p-toluensulfonil skupinom; ili
- acil skupinom formule R1a-CO, gdje R1a znači C1-4 alkil skupinu, fenil skupinu; fenil, piridil ili feniletenil skupina supstituirana s jednom ili više alkil- i/ili alkoksi- ili nitro-skupina ili atom halogena; feniletenil ili feniletil skupina substituirana s alkilen-dioksi skupinom; piperidin-1-il, 4-metilpiperazin-1-il, pirolidin-1-il skupinu,
B stoj i za
- skupinu formule (6) ili (7);
R2 stoji za atom vodika ili atom fluora;
R3 stoji za atom fluora -
i njihove soli, izomere, tautomere, solvate i hidrate.
8. Spojevi zahtjeva 2 i 3 opće formule (I) naznačeni time, da R znači 2-pirimidinil, 2-pirazinil, klor- i cijano-substituiran piridazinil, cijano-substituiran 2-piridinil; B stoji za skupinu formule (1); R2 i R3 stoje za atom fluora.
9. Spojevi zahtjeva 2 i 4 opće formule (I) naznačeni time, da R1 znači 2-pirimidinil, 2-pirazinil, klor- i cijano-substituiran piridazinil, cijano-substituiran 2-piridinil; B stoji za skupinu formule (2); R2 i R3 stoje za atom fluora.
10. Spojevi zahtjeva 2 i 5 opće formule (I) naznačeni time, da R1 znači 2-pirimidinil, 2-pirazinil, klor- i cijano-substituiran piridazinil, cijano-substituiran 2-piridinil; B stoji za skupinu formule (3); R2 i R3 stoje za atom fluora.
11. Spojevi zahtjeva 2 i 6 opće formule (I) naznačeni time, da R1 znači 2-pirimidinil, 2-pirazinil, klor- i cijano-substituiran piridazinil, cijano-substituiran 2-piridinil; B stoji za skupinu formule (4) ili (5) ; R2 i R3 stoje za atom fluora.
12. Spojevi zahtjeva 2 i 7 opće formule (I) naznačeni time, da R1 znači 2-pirimidinil, 2-pirazinil, klor- i cijano-substituiran piridazinil, cijano-substituiran 2-piridinil; B stoji za skupinu formule (6) ili (7); R2 i R3 stoje za atom fluora.
13. Spoj naznačen time, da je (2S)-4,4-difluor-1-(2-{[8-(2-pirimidinil)-8-azabiciklo[3.2.1]okt-3-il]exo-amino}acetil)-2-pirolidin karbonitril.
14. Spoj naznačen time, da je (2S,4S)-4-fluor-1-(2-{[8-(2-pirazinil)-8-azabiciklo[3.2.1]okt-3-il]exo-amino}acetil)-2-pirolidinkarbonitril.
15. Spoj naznačen time, da je (2S)-4,4-difluor-1-(2-{[1-(2-pirazinil)piperidin-4-il]amino}acetil)-2-pirolidin karbonitril.
16. Spoj naznačen time, da je (2S)-4,4-difluor-1-(2-{[1-(5-cijanopiridin-4-il]amino}acetil)-2-pirolidin karbonitril.
17. Spoj naznačen time, da je (2S)-4,4-difluor-1-(2-{[1-(6-klorpiridazin-3-il)piperidin-4-il]amino}acetil)-2-pirolidin karbonitril.
18. Spoj naznačen time, da je (2S)-4,4-difluor-1-(2-{[1-(6-cijanopiridazin-3-il)piperidin-4-il]amino}acetil)-2-pirolidin karbonitril.
19. Farmaceutske formulacije naznačene time, da obuhvaćaju spoj opće formule (I) u skladu sa zahtjevima 1 do 18 ili njihove soli, izomere, tautomere, solvate, hidrate.
20. Postupak proizvodnje spojeva opće formule (I) gdje je značenje R1, B, R2 i R3 isto kao što je definirano u zahtjevima 1 do 12 naznačen time, da spoj opće formule (II)- gdje je značenje R1 i B kao što je definirano gore - reagirao sa spojem opće formule (III)- gdje je značenje R2 i R3 kao što je definirano gore - a nastali spoj opće formule (I) ili njegova sol su izolirani iz reakcijske smjese.
21. Upotreba spoja opće formule (I)- gdje značenja R1, B, R2 i R3 su ista kao što je definirano u zahtjevima 1 do 12-naznačena time, da je za proizvodnju farmaceutske formulacije koja je pogodna za inhibiciju aktivnosti DPP-IV enzima, i namijenjen je za tretiranje i prevenciju bolesti povezanih s aktivnosti DPP-IV enzima.
22. Upotreba spoja opće formule (I)- gdje značenja R1, B, R2 i R3 su ista kao što je definirano u zahtjevima 1 do 12-naznačena time, da je za proizvodnju farmaceutske formulacije koja je pogodna za inhibiciju aktivnosti DPP-IV enzima, i namijenjen je za tretiranje i prevenciju dijabetesa.
23. Spojevi naznačeni time, da su spoj opće formule (II) gdje je značenje R1 i B kao što je definirano u zahtjevima 1 do 12-i njegovi izomeri i soli.
24. Spojevi naznačeni time, da su spoj opće formule (III) gdje je značenje R2 i R3 kao što je definirano u zahtjevima 1 do 12 - i njegovi izomeri.
25. Spojevi naznačeni time, da su spoj opće formule (V)- gdje je značenje R1 i B kao što je definirano u zahtjevima 1 do 12, Y stoji za acetil ili tert-butoksikarbonil skupinu - i njegovi izomeri i soli.
26. Spojevi naznačeni time, da su spoj opće formule (VII)-gdje je značenje R2 i R3 kao što je definirano u zahtjevima 1 do 12 - i njegovi izomeri.
27. Spojevi naznačeni time, da su spoj opće formule (VIII)-gdje je značenje R2 i R3 kao što je definirano u zahtjevima 1 do 12 - i njegovi izomeri i soli.
28. Spojevi naznačeni time, da su spoj opće formule (IX) gdje je značenje R2 i R3 kao što je definirano u zahtjevima 1 do 12 - i njegovi izomeri.
29. Upotreba spojeva opće formule (II), (III), (V), (VII), (VIII) i (IX) naznačena time, da je u skladu sa zahtjevima 22 do 27 za proizvodnju spojeva opće formule (I) definiranom u zahtjevima 1 do 18.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0200849A HUP0200849A2 (hu) | 2002-03-06 | 2002-03-06 | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
PCT/HU2003/000017 WO2003074500A2 (en) | 2002-03-06 | 2003-03-04 | N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20040910A2 true HRP20040910A2 (en) | 2006-02-28 |
Family
ID=90001540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20040910A HRP20040910A2 (en) | 2002-03-06 | 2004-10-04 | New compounds |
Country Status (28)
Country | Link |
---|---|
US (3) | US7348327B2 (hr) |
EP (1) | EP1487807B1 (hr) |
JP (1) | JP4559737B2 (hr) |
KR (1) | KR100977898B1 (hr) |
CN (2) | CN1990486A (hr) |
AR (1) | AR038868A1 (hr) |
AT (1) | ATE443054T1 (hr) |
AU (1) | AU2003209514B2 (hr) |
BR (1) | BR0307960A (hr) |
CA (1) | CA2475312C (hr) |
DE (1) | DE60329282D1 (hr) |
EA (1) | EA007410B1 (hr) |
EC (1) | ECSP045274A (hr) |
HR (1) | HRP20040910A2 (hr) |
HU (1) | HUP0200849A2 (hr) |
IL (2) | IL163286A (hr) |
IS (1) | IS7434A (hr) |
MA (1) | MA27105A1 (hr) |
MX (1) | MXPA04008613A (hr) |
NO (1) | NO20044221L (hr) |
NZ (1) | NZ535662A (hr) |
PL (1) | PL371099A1 (hr) |
RS (1) | RS79004A (hr) |
TN (1) | TNSN04141A1 (hr) |
TW (1) | TWI250978B (hr) |
UA (1) | UA78291C2 (hr) |
WO (1) | WO2003074500A2 (hr) |
ZA (1) | ZA200406467B (hr) |
Families Citing this family (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE370943T1 (de) * | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
HUP0202001A2 (hu) * | 2002-06-14 | 2005-08-29 | Sanofi-Aventis | DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok |
TW200401635A (en) * | 2002-07-23 | 2004-02-01 | Yamanouchi Pharma Co Ltd | 2-Cyano-4-fluoropyrrolidine derivative or salt thereof |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
WO2004098591A2 (en) | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases |
HU227684B1 (en) * | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
EP1680120A2 (en) | 2003-11-03 | 2006-07-19 | Probiodrug AG | Combinations useful for the treatment of neuronal disorders |
KR20140089408A (ko) * | 2003-11-17 | 2014-07-14 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
PT1715893E (pt) | 2004-01-20 | 2009-10-20 | Novartis Pharma Ag | Formulação para compressão directa e processos |
KR101130433B1 (ko) | 2004-02-05 | 2012-03-27 | 교린 세이야꾸 가부시키 가이샤 | 비시클로에스테르 유도체 |
CN1918131B (zh) | 2004-02-05 | 2011-05-04 | 前体生物药物股份公司 | 谷氨酰胺酰基环化酶抑制剂 |
FR2870538B1 (fr) * | 2004-05-19 | 2006-07-14 | Servier Lab | Nouveaux derives de pyrrolidines et de thiazolidines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EA013463B1 (ru) | 2004-10-12 | 2010-04-30 | ГЛЕНМАРК ФАРМАСЬЮТИКАЛС Эс.Эй. | Новые ингибиторы дипептидилпептидазы iv, содержащие их фармацевтические композиции, способ их получения и способ лечения с их применением |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
JP2008024592A (ja) * | 2005-01-28 | 2008-02-07 | Taisho Pharmaceut Co Ltd | シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法 |
AU2006239929B2 (en) | 2005-04-22 | 2011-11-03 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-IV inhibitors |
MX2008001799A (es) * | 2005-08-11 | 2008-04-16 | Hoffmann La Roche | Composicion farmaceutica que comprende un inhibidor de dipeptidil peptidasa iv. |
WO2007033350A1 (en) | 2005-09-14 | 2007-03-22 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
EP1924567B1 (en) | 2005-09-16 | 2012-08-22 | Takeda Pharmaceutical Company Limited | Process for the preparation of pyrimidinedione derivatives |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
US20090156465A1 (en) | 2005-12-30 | 2009-06-18 | Sattigeri Jitendra A | Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors |
CN101395131B (zh) | 2006-03-08 | 2012-11-14 | 杏林制药株式会社 | 氨基乙酰基吡咯烷甲腈衍生物的制备方法及其制备中间体 |
CN101050194B (zh) * | 2006-04-05 | 2013-08-21 | 上海恒瑞医药有限公司 | 双环辛烷类衍生物、其制备方法及其在医药上的用途 |
AR060406A1 (es) * | 2006-04-11 | 2008-06-11 | Arena Pharm Inc | Metodos para usar el receptor gpr119 en la identificacion de compuestos utiles para aumentar la masa osea en un individuo |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
MX2008014024A (es) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Formas poliformas. |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
SI2091948T1 (sl) | 2006-11-30 | 2012-07-31 | Probiodrug Ag | Novi inhibitorji glutaminil ciklaze |
CN101230058A (zh) * | 2007-01-23 | 2008-07-30 | 上海恒瑞医药有限公司 | 双环氮杂烷类衍生物、其制备方法及其在医药上的用途 |
CN101230059B (zh) * | 2007-01-23 | 2011-08-17 | 上海恒瑞医药有限公司 | 双环氮杂烷类衍生物、其制备方法及其在医药上的用途 |
DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
JPWO2008114857A1 (ja) | 2007-03-22 | 2010-07-08 | 杏林製薬株式会社 | アミノアセチルピロリジンカルボニトリル誘導体の製造方法 |
DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
EP2155689B1 (en) | 2007-05-31 | 2015-07-08 | Boehringer Ingelheim International GmbH | Ccr2 receptor antagonists and uses thereof |
GB0713602D0 (en) * | 2007-07-12 | 2007-08-22 | Syngenta Participations Ag | Chemical compounds |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2009037719A1 (en) * | 2007-09-21 | 2009-03-26 | Lupin Limited | Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors |
JP5438028B2 (ja) * | 2008-01-23 | 2014-03-12 | ジエンス ハンセン ファーマセウティカル カンパニー リミテッド | アザビシクロオクタンの誘導体、その製造方法及びそのジペプチジルペプチダーゼivの阻害剤としての用途 |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
EP2146210A1 (en) * | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
CA2732984A1 (en) | 2008-08-07 | 2010-02-11 | Kyorin Pharmaceutical Co., Ltd. | Process for production of bicyclo[2.2.2]octylamine derivative |
CN102186474A (zh) * | 2008-08-14 | 2011-09-14 | 杏林制药株式会社 | 稳定的医药组合物 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
WO2010054183A2 (en) * | 2008-11-07 | 2010-05-14 | President And Fellows Of Harvard College | Dyes, compositions and related methods of use |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
MA33085B1 (fr) | 2008-12-19 | 2012-03-01 | Boehringer Ingelheim Int | Pyrimidine-4 carboxamides cycliques en tant qu'antagonistes du recepteur ccr2 pour le traitement d'inflammations, de l'asthme et des broncho-pneumopathies chroniques obstructives |
GB2483614B (en) | 2009-06-18 | 2014-12-03 | Lupin Ltd | 2-Amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
AU2010294214B2 (en) | 2009-09-11 | 2015-05-07 | Vivoryon Therapeutics N.V. | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
EP3646859A1 (en) | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
JP5632014B2 (ja) | 2009-12-17 | 2014-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ccr2受容体アンタゴニスト及びこれらの使用 |
JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
CN102918027A (zh) | 2010-04-06 | 2013-02-06 | 艾尼纳制药公司 | Gpr119受体调节剂和对与所述受体有关的障碍的治疗 |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
AU2011249722B2 (en) | 2010-05-05 | 2015-09-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
WO2011141474A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
WO2011141477A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
WO2011144501A1 (en) | 2010-05-17 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Ccr2 antagonists and uses thereof |
US9018212B2 (en) | 2010-05-25 | 2015-04-28 | Boehringer Ingelheim International Gmbh | Pyridazine carboxamides as CCR2 receptor antagonists |
WO2011151251A1 (en) | 2010-06-01 | 2011-12-08 | Boehringer Ingelheim International Gmbh | New ccr2 antagonists |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013010839A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Novel and selective ccr2 antagonists |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
CA2873097A1 (en) * | 2012-05-11 | 2013-11-14 | Todd M. Hansen | Pyridazine and pyridine derivatives as nampt inhibitors |
EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
EP2865666B1 (en) | 2012-06-25 | 2017-05-31 | Sunshine Lake Pharma Co., Ltd. | Hexahydropentaleno derivatives, preparation method and use in medicine thereof |
TWI500613B (zh) | 2012-10-17 | 2015-09-21 | Cadila Healthcare Ltd | 新穎之雜環化合物 |
EP2911655A1 (en) | 2012-10-24 | 2015-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
EP3085700B1 (en) * | 2013-12-20 | 2018-10-31 | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China | Novel piperidine carboxamide compound, preparation method, and usage thereof |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
CN104529858A (zh) * | 2015-01-13 | 2015-04-22 | 佛山市赛维斯医药科技有限公司 | 含卤代金刚烷和酰胺类衍生物、其制备方法和用途 |
CN104529856A (zh) * | 2015-01-13 | 2015-04-22 | 佛山市赛维斯医药科技有限公司 | 一种硝基金刚烷酰胺衍生物、其制备方法和用途 |
EP3053577A1 (en) * | 2015-02-09 | 2016-08-10 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
EP3256126B1 (en) | 2015-02-09 | 2024-03-27 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
DK3265126T3 (da) | 2015-03-03 | 2021-09-13 | Saniona As | Kombinationsformulering af tesofensin og metoprolol |
CA2979033A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
ES2805743T3 (es) | 2015-03-24 | 2021-02-15 | Inst Nat Sante Rech Med | Método y composición farmacéutica para uso en el tratamiento de la diabetes |
WO2017004537A1 (en) | 2015-07-02 | 2017-01-05 | Centrexion Therapeutics Corporation | (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate |
BR112018072401A2 (pt) | 2016-06-10 | 2019-02-19 | Boehringer Ingelheim International Gmbh | combinações de linagliptina e metformina |
WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
CN110996951A (zh) | 2017-04-03 | 2020-04-10 | 科赫罗斯生物科学股份有限公司 | 治疗进行性核上性麻痹的PPARγ激动剂 |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
RU2020122712A (ru) | 2017-12-15 | 2022-01-18 | ПРАКСИС БАЙОТЕК ЭлЭлСи | Ингибиторы белка активации фибробластов |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2005A (en) * | 1841-03-16 | Improvement in the manner of constructing molds for casting butt-hinges | ||
US2004A (en) * | 1841-03-12 | Improvement in the manner of constructing and propelling steam-vessels | ||
US3225037A (en) | 1959-03-30 | 1965-12-21 | Sterling Drug Inc | 10-[(amino- and acylamino-1-piperidyl) lower-alkyl]-phenothiazines |
GB1460389A (en) * | 1974-07-25 | 1977-01-06 | Pfizer Ltd | 4-substituted quinazoline cardiac stimulants |
US4302455A (en) * | 1980-04-14 | 1981-11-24 | Merck & Co., Inc. | 2-(4-Aminopiperidino)pyrazines |
US5001125A (en) * | 1984-03-26 | 1991-03-19 | Janssen Pharmaceutica N.V. | Anti-virally active pyridazinamines |
JP2869561B2 (ja) * | 1989-05-22 | 1999-03-10 | 大塚製薬株式会社 | 血小板粘着抑制剤 |
CA2106840A1 (en) * | 1992-09-25 | 1994-03-26 | Marco Baroni | Heteroarylazetidines and -pyrrolidines, process for their preparation and pharmaceutical compositions containing them |
ES2079323B1 (es) * | 1994-06-21 | 1996-10-16 | Vita Invest Sa | Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes. |
UA51716C2 (uk) * | 1996-07-08 | 2002-12-16 | Авентіс Фармасьютікалз Продактс Інк. | Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування |
TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
FR2780057B1 (fr) | 1998-06-18 | 2002-09-13 | Sanofi Sa | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant |
EP1178982B1 (en) * | 1999-05-21 | 2004-06-30 | Abbott Laboratories | Heterocyclic substituted aminoazacycles useful as central nervous system agents |
TW583185B (en) * | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
EP1950199B1 (en) | 2000-08-10 | 2009-12-02 | Mitsubishi Tanabe Pharma Corporation | Proline derivatives and use thereof as drugs |
KR100526091B1 (ko) * | 2000-10-06 | 2005-11-08 | 다나베 세이야꾸 가부시키가이샤 | 지방족 질소 함유 오원환 화합물 |
TWI243162B (en) * | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
JP2002264450A (ja) * | 2000-12-21 | 2002-09-18 | Ricoh Co Ltd | 画像処理ユニット、画像形成装置、画像形成方法及び画像処理システム |
JPWO2002051836A1 (ja) * | 2000-12-27 | 2004-04-22 | 協和醗酵工業株式会社 | ジペプチジルペプチダーゼ−iv阻害剤 |
GB0115517D0 (en) * | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
IL158923A0 (en) * | 2001-06-27 | 2004-05-12 | Smithkline Beecham Corp | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
ATE370943T1 (de) | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
WO2004000799A1 (en) | 2002-06-20 | 2003-12-31 | Akzo Nobel N.V. | (stabilised) peroxide compositions phlegmatised with a specific unsaturated phlegmatising agent |
TW200401635A (en) | 2002-07-23 | 2004-02-01 | Yamanouchi Pharma Co Ltd | 2-Cyano-4-fluoropyrrolidine derivative or salt thereof |
CN1706726A (zh) * | 2004-02-17 | 2005-12-14 | 梅加特雷德国际公司 | 带发光部件的容器 |
-
2002
- 2002-03-06 HU HU0200849A patent/HUP0200849A2/hu unknown
-
2003
- 2003-03-04 CN CNA2006101640208A patent/CN1990486A/zh active Pending
- 2003-03-04 EA EA200401157A patent/EA007410B1/ru not_active IP Right Cessation
- 2003-03-04 JP JP2003572969A patent/JP4559737B2/ja not_active Expired - Fee Related
- 2003-03-04 DE DE60329282T patent/DE60329282D1/de not_active Expired - Lifetime
- 2003-03-04 KR KR1020047013870A patent/KR100977898B1/ko not_active IP Right Cessation
- 2003-03-04 WO PCT/HU2003/000017 patent/WO2003074500A2/en active Application Filing
- 2003-03-04 AT AT03743452T patent/ATE443054T1/de not_active IP Right Cessation
- 2003-03-04 AU AU2003209514A patent/AU2003209514B2/en not_active Ceased
- 2003-03-04 CN CNA038052636A patent/CN1639159A/zh active Pending
- 2003-03-04 MX MXPA04008613A patent/MXPA04008613A/es active IP Right Grant
- 2003-03-04 RS YU79004A patent/RS79004A/sr unknown
- 2003-03-04 US US10/507,005 patent/US7348327B2/en not_active Expired - Fee Related
- 2003-03-04 CA CA2475312A patent/CA2475312C/en not_active Expired - Fee Related
- 2003-03-04 EP EP03743452A patent/EP1487807B1/en not_active Expired - Lifetime
- 2003-03-04 PL PL03371099A patent/PL371099A1/xx not_active Application Discontinuation
- 2003-03-04 NZ NZ535662A patent/NZ535662A/en unknown
- 2003-03-04 BR BR0307960-0A patent/BR0307960A/pt not_active IP Right Cessation
- 2003-03-05 AR ARP030100723A patent/AR038868A1/es unknown
- 2003-03-06 TW TW092104743A patent/TWI250978B/zh not_active IP Right Cessation
- 2003-04-03 UA UA20041008080A patent/UA78291C2/uk unknown
-
2004
- 2004-07-29 IL IL163286A patent/IL163286A/en not_active IP Right Cessation
- 2004-07-29 MA MA27806A patent/MA27105A1/fr unknown
- 2004-07-29 TN TNP2004000141A patent/TNSN04141A1/en unknown
- 2004-08-13 ZA ZA200406467A patent/ZA200406467B/en unknown
- 2004-09-02 IS IS7434A patent/IS7434A/is unknown
- 2004-09-03 EC EC2004005274A patent/ECSP045274A/es unknown
- 2004-10-04 HR HR20040910A patent/HRP20040910A2/hr not_active Application Discontinuation
- 2004-10-05 NO NO20044221A patent/NO20044221L/no not_active Application Discontinuation
-
2006
- 2006-09-07 IL IL177933A patent/IL177933A0/en unknown
-
2008
- 2008-03-05 US US12/042,595 patent/US7655663B2/en not_active Expired - Fee Related
-
2010
- 2010-02-01 US US12/697,762 patent/US8063045B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20040910A2 (en) | New compounds | |
JP4502804B2 (ja) | Ddp−iv阻害活性を有するアザビシクロ−オクタン及びノナン誘導体 | |
AU2004268832B2 (en) | Adamantane and azabicyclo-octane and nonane derivatives, process of their preparation and their use as DPP-IV inhibitors | |
JP2005511541A (ja) | プロリン後切断プロテアーゼの阻害剤 | |
WO2004026822A2 (en) | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv) | |
WO2005077900A1 (ja) | ビシクロアミド誘導体 | |
CN116473965A (zh) | 吡唑magl抑制剂 | |
WO2004081005A1 (en) | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | |
EP2308847A1 (en) | Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20070208 Year of fee payment: 5 |
|
OBST | Application withdrawn |